Search results
Results from the WOW.Com Content Network
Valeant raised its unsolicited offer for Allergan a second time, to $53.3 billion, increasing the cash portion of the bid in an effort to win the backing of the company, with the cash-and-stock portion of the bid valuing each Allergan share at $179.25. [26] 16 2014 Valeant Pharmaceuticals: Allergan, Inc: 49.4 64
Novartis also initiated a program to assist patients who could not afford its version of the drug, concurrent with its product launch. [175] When examination of Novartis' patent application began in 2005, it came under immediate attack from oppositions initiated by generic companies that were already selling Gleevec in India and by advocacy ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
With another earnings season upon us, The Fool's health care team is busy making sure investors know what to expect from their favorite companies this quarter, while also maintaining a focus on ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
Chiron was the first to clone HCV in 1989 after six years of research [8] and had since filed over 100 HCV related patents in over 20 countries. [31] A settlement was reached where Roche Holding A.G. agreed to buy the global semi-exclusive nucleic acid test (NAT) patents for HCV and HIV from Chiron. [25]
This video is part of our "Motley Fool Conversations" series, in which Million Dollar Portfolio advisor Charly Travers and Motley Fool Stock Advisor analyst Jason Moser discuss topics Top 10 ...